<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39465409</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>28</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>29</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1756-0500</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>27</Day></PubDate></JournalIssue><Title>BMC research notes</Title><ISOAbbreviation>BMC Res Notes</ISOAbbreviation></Journal><ArticleTitle>The silent predictors: exploring galectin-3 and Irisin's tale in severe COVID-19.</ArticleTitle><Pagination><StartPage>324</StartPage><MedlinePgn>324</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">324</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13104-024-06978-3</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">This study aimed to evaluate the roles of galectin-3 and irisin as biomarkers in predicting severe outcomes in COVID-19 patients.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We analyzed serum levels of galectin-3 and irisin in 59 patients with severe COVID-19 and 30 healthy controls. Elevated galectin-3 levels were associated with increased risks of mortality, need for intensive care, and severe acute respiratory distress syndrome. The optimal cut-off value for galectin-3 was 13.47 ng/ml, with a sensitivity of 72.7% and specificity of 76.6%. Irisin levels did not differ significantly between survivors and non-survivors at admission or on the 3rd day post-admission, but approached significance on the 7th day. These findings suggest that galectin-3 could be a valuable prognostic biomarker for severe COVID-19 outcomes, while irisin's role remains to be clarified in further studies.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Nikolic</LastName><ForeName>Valentina N</ForeName><Initials>VN</Initials><AffiliationInfo><Affiliation>Department of Pharmacology with Toxicology, University of Nis Faculty of Medicine, Bul. dr Zorana Djindjica 81 Nis, Nis, 18000, Serbia. valentina@medfak.ni.ac.rs.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Popadic</LastName><ForeName>Višeslav</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>University Hospital Medical Center, Bezanijska kosa, Belgrade, Serbia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jankovic</LastName><ForeName>Slobodan M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Toxicology, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Govedarović</LastName><ForeName>Nenad</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, University of Nis Faculty of Medicine, Nis, Serbia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vujić</LastName><ForeName>Stevan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>University of Nis Faculty of Medicine, Nis, Serbia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andjelković</LastName><ForeName>Jelica</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>University of Nis Faculty of Medicine, Nis, Serbia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stosic</LastName><ForeName>Lazar S</ForeName><Initials>LS</Initials><AffiliationInfo><Affiliation>University of Nis Faculty of Medicine, Nis, Serbia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stevanović</LastName><ForeName>Nikola Č</ForeName><Initials>NČ</Initials><AffiliationInfo><Affiliation>University of Nis Faculty of Medicine, Nis, Serbia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zdravkovic</LastName><ForeName>Marija</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>University Hospital Medical Center, Bezanijska kosa, Belgrade, Serbia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, Faculty of Medicine, University of Belgrade, Belgrade, Serbia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Todorovic</LastName><ForeName>Zoran</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>University Hospital Medical Center, Bezanijska kosa, Belgrade, Serbia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmacology, Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Belgrade, Belgrade, Serbia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>451-03-66/2024-03/200113</GrantID><Agency>Ministry of Education, Science and Technological Development, Republic of Serbia</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Res Notes</MedlineTA><NlmUniqueID>101462768</NlmUniqueID><ISSNLinking>1756-0500</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005353">Fibronectins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C577593">FNDC5 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D037502">Galectin 3</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C428445">LGALS3 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D037161">Galectins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001798">Blood Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005353" MajorTopicYN="Y">Fibronectins</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="Y">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D037502" MajorTopicYN="Y">Galectin 3</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D037161" MajorTopicYN="N">Galectins</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001798" MajorTopicYN="N">Blood Proteins</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012128" MajorTopicYN="N">Respiratory Distress Syndrome</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Biomarker discovery</Keyword><Keyword MajorTopicYN="N">COVID-19 prognosis</Keyword><Keyword MajorTopicYN="N">Galectin-3</Keyword><Keyword MajorTopicYN="N">Irisin</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2 infection</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>28</Day><Hour>12</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>28</Day><Hour>6</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>28</Day><Hour>5</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39465409</ArticleId><ArticleId IdType="doi">10.1186/s13104-024-06978-3</ArticleId><ArticleId IdType="pii">10.1186/s13104-024-06978-3</ArticleId><ArticleId IdType="pmc">PMC11514771</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization. COVID-19Weekly Epidemiological Update. Edition 50 Published 27 July 2021. Available online: https://www.who.int/emergencies/diseases/novel-coronavirus-2019? (accessed on 14 March 2024).</Citation></Reference><Reference><Citation>Berlin DA, Gulick RM, Martinez FJ. Severe Covid-19. N Engl J Med. 2020;383(25):2451–2460. doi: 10.1056/NEJMcp2009575. Epub 2020 May 15. PMID: 32412710.</Citation><ArticleIdList><ArticleId IdType="pubmed">32412710</ArticleId></ArticleIdList></Reference><Reference><Citation>Napoli C, Benincasa G, Criscuolo C, Faenza M, Liberato C, Rusciano M. Immune reactivity during COVID-19: implications for treatment. Immunol Lett. 2021;231:28–34. 10.1016/j.imlet.2021.01.001.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7787505</ArticleId><ArticleId IdType="pubmed">33421440</ArticleId></ArticleIdList></Reference><Reference><Citation>Santos A, Magro DO, Evangelista-Poderoso R, Saad MJA. Diabetes, obesity, and insulin resistance in COVID-19: molecular interrelationship and therapeutic implications. Diabetol Metab Syndr. 2021;13(1):23. 10.1186/s13098-021-00639-2. PMID: 33648564; PMCID: PMC7919999.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7919999</ArticleId><ArticleId IdType="pubmed">33648564</ArticleId></ArticleIdList></Reference><Reference><Citation>Lima-Martínez MM, Carrera Boada C, Madera-Silva MD, Marín W, Contreras M. COVID-19 and diabetes: a bidirectional relationship. Clin Investig Arterioscler. 2021 May-Jun;33(3):151–7. 10.1016/j.arteri.2020.10.001. English, Spanish.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7598432</ArticleId><ArticleId IdType="pubmed">33303218</ArticleId></ArticleIdList></Reference><Reference><Citation>Perakakis N, Triantafyllou GA, Fernández-Real JM, Huh JY, Park KH, Seufert J, Mantzoros CS. Physiology and role of irisin in glucose homeostasis. Nat Rev Endocrinol. 2017;13(6):324–37. 10.1038/nrendo.2016.221. Epub 2017 Feb 17. PMID: 28211512; PMCID: PMC5878942.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5878942</ArticleId><ArticleId IdType="pubmed">28211512</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu W, Sahar NE, Javaid HMA, Pak ES, Liang G, Wang Y, et al. Exercise- Induced Irisin decreases inflammation and improves NAFLD by competitive binding with MD2. Cells. 2021;10:3306. 10.3390/cells10123306.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8699279</ArticleId><ArticleId IdType="pubmed">34943814</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu FT, Stowell SR. The role of galectins in immunity and infection. Nat Rev Immunol. 2023;23(8):479–94. 10.1038/s41577-022-00829-7. Epub 2023 Jan 16. PMID: 36646848; PMCID: PMC9842223.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9842223</ArticleId><ArticleId IdType="pubmed">36646848</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaughan EE, Quinn TM, Mills A, Bruce AM, Antonelli J, MacKinnon AC, Aslanis V, Li F, O’Connor R, Boz C, Mills R, Emanuel P, Burgess M, Rinaldi G, Valanciute A, Mills B, Scholefield E, Hardisty G, Findlay EG, Parker RA, Norrie J, Dear JW, Akram AR, Koch O, Templeton K, Dockrell DH, Walsh TS, Partridge S, Humphries D, Wang-Jairaj J, Slack RJ, Schambye H, Phung D, Gravelle L, Lindmark B, Shankar-Hari M, Hirani N, Sethi T, Dhaliwal K. An inhaled Galectin-3 inhibitor in COVID-19 pneumonitis: a phase Ib/IIa Randomized Controlled Clinical Trial (DEFINE). Am J Respir Crit Care Med. 2023;207(2):138–49. 10.1164/rccm.202203-0477OC. PMID: 35972987; PMCID: PMC9893334.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9893334</ArticleId><ArticleId IdType="pubmed">35972987</ArticleId></ArticleIdList></Reference><Reference><Citation>Schroeder JT, Bieneman AP. The S1 subunit of the SARS-CoV-2 spike protein activates human monocytes to produce cytokines linked to COVID-19: relevance to Galectin-3. Front Immunol. 2022;13:831763. 10.3389/fimmu.2022.831763. PMID: 35392091; PMCID: PMC8982143.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8982143</ArticleId><ArticleId IdType="pubmed">35392091</ArticleId></ArticleIdList></Reference><Reference><Citation>Gajovic N, Markovic SS, Jurisevic M, Jovanovic M, Arsenijevic N, Mijailovic Z, Jovanovic M, Jovanovic I. Galectin-3 as an important prognostic marker for COVID-19 severity. Sci Rep. 2023;13(1):1460. 10.1038/s41598-023-28797-5. PMID: 36702907; PMCID: PMC9878495.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9878495</ArticleId><ArticleId IdType="pubmed">36702907</ArticleId></ArticleIdList></Reference><Reference><Citation>Özcan S, Dönmez E, Yavuz ST, Ziyrek M, İnce O, Küçük HS, Taşdemir ZA, Yılmaz İ, Varol S, Şahin İ, Okuyan E. Prognostic significance of serum galectin-3 in hospitalized patients with COVID-19. Cytokine. 2022;158:155970. 10.1016/j.cyto.2022.155970. Epub 2022 Jul 28. PMID: 35917725; PMCID: PMC9329148.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9329148</ArticleId><ArticleId IdType="pubmed">35917725</ArticleId></ArticleIdList></Reference><Reference><Citation>Cervantes-Alvarez E, la Rosa NL, la Mora MS, Valdez-Sandoval P, Palacios-Jimenez M, Rodriguez-Alvarez F, Vera-Maldonado BI, Aguirre-Aguilar E, Escobar-Valderrama JM, Alanis-Mendizabal J, Méndez-Guerrero O, Tejeda-Dominguez F, Torres-Ruíz J, Gómez-Martín D, Colborn KL, Kershenobich D, Huang CA, Navarro-Alvarez N. Galectin-3 as a potential prognostic biomarker of severe COVID-19 in SARS-CoV-2 infected patients. Sci Rep. 2022;12(1):1856. 10.1038/s41598-022-05968-4. PMID: 35115644; PMCID: PMC8813958.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8813958</ArticleId><ArticleId IdType="pubmed">35115644</ArticleId></ArticleIdList></Reference><Reference><Citation>Portacci A, Diaferia F, Santomasi C, Dragonieri S, Boniello E, Di Serio F, Carpagnano GE. Galectin-3 as prognostic biomarker in patients with COVID-19 acute respiratory failure. Respir Med. 2021;187:106556. 10.1016/j.rmed.2021.106556. Epub 2021 Aug 4. PMID: 34375925; PMCID: PMC8332745.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8332745</ArticleId><ArticleId IdType="pubmed">34375925</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Revilla J, Deierborg T, Venero JL, Boza-Serrano A. Hyperinflammation and fibrosis in severe COVID-19 patients: Galectin-3, a target molecule to consider. Front Immunol. 2020;11:2069. 10.3389/fimmu.2020.02069.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7461806</ArticleId><ArticleId IdType="pubmed">32973815</ArticleId></ArticleIdList></Reference><Reference><Citation>Sigamani A, Mayo KH, Miller MC, Chen-Walden H, Reddy S, Platt D. An oral galectin inhibitor in COVID-19-A Phase II Randomized Controlled Trial. Vaccines (Basel). 2023;11(4):731. 10.3390/vaccines11040731. PMID: 37112643; PMCID: PMC10140888.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10140888</ArticleId><ArticleId IdType="pubmed">37112643</ArticleId></ArticleIdList></Reference><Reference><Citation>Jover E, Matilla L, Garaikoetxea M, Fernández-Celis A, Muntendam P, Jaisser F, Rossignol P, López-Andrés N. Beneficial effects of Mineralocorticoid receptor pathway blockade against endothelial inflammation Induced by SARS-CoV-2 Spike Protein. Biomedicines. 2021;9(6):639. 10.3390/biomedicines9060639. PMID: 34204890; PMCID: PMC8228852.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8228852</ArticleId><ArticleId IdType="pubmed">34204890</ArticleId></ArticleIdList></Reference><Reference><Citation>de Oliveira M, De Sibio MT, Mathias LS, Rodrigues BM, Sakalem ME, Nogueira CR. Irisin modulates genes associated with severe coronavirus disease (COVID-19) outcome in human subcutaneous adipocytes cell culture. Mol Cell Endocrinol. 2020;515:110917. 10.1016/j.mce.2020.110917.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7315947</ArticleId><ArticleId IdType="pubmed">32593740</ArticleId></ArticleIdList></Reference><Reference><Citation>Alves HR, Lomba GSB, Gonçalves-de-Albuquerque CF, Burth P. Irisin, Exercise, and COVID-19. Front Endocrinol (Lausanne). 2022;13:879066. 10.3389/fendo.2022.879066.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9248970</ArticleId><ArticleId IdType="pubmed">35784579</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>